NCT03755193

Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

Examination of Efficacy and Safety of SERM or Bisphosphonates After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Shinshu University · Academic / Other
• Sex: All
• Age: 20 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy: SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months

Conditions

• Osteoporosis

Interventions

Type	Name	Description
DRUG	SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"	To examine the effects of SERM and ELD in osteoporosis patients
DRUG	Bisphosphonates and ELD "Edirol®Tablet 0.75ug"	To examine the effects of BP and ELD in osteoporosis patients
DRUG	ELD "Edirol®Tablet 0.75ug"	To examine the effects of ELD in osteoporosis patients

Timeline

• Start date: 2018-11-24
• Primary completion: 2024-11-23
• Completion: 2026-11-23
• First posted: 2018-11-27
• Last updated: 2021-09-21

Locations

1 site across 1 country: Japan